LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Recursion Pharmaceuticals Inc

Fermé

SecteurSoins de santé

4.69 -3.1

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.57

Max

4.88

Chiffres clés

By Trading Economics

Revenu

31M

-172M

Ventes

4.4M

19M

Marge bénéficiaire

-899.843

Employés

800

EBITDA

44M

-148M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+24.74% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-432M

2.1B

Ouverture précédente

7.79

Clôture précédente

4.69

Sentiment de l'Actualité

By Acuity

50%

50%

185 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 sept. 2025, 17:03 UTC

Principaux Mouvements du Marché

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept. 2025, 16:49 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

GD Culture Shares Drop After Deal for Pallas Capital

16 sept. 2025, 16:11 UTC

Principaux Mouvements du Marché

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept. 2025, 21:10 UTC

Acquisitions, Fusions, Rachats

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 sept. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

16 sept. 2025, 20:25 UTC

Résultats

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept. 2025, 20:24 UTC

Résultats

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept. 2025, 18:40 UTC

Acquisitions, Fusions, Rachats

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept. 2025, 16:53 UTC

Résultats

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

16 sept. 2025, 16:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Commodities Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Energy Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparaison

Variation de prix

Recursion Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

24.74% hausse

Prévisions sur 12 Mois

Moyen 5.95 USD  24.74%

Haut 8 USD

Bas 3 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

1

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

4.15 / 4.75Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

185 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat